BIO
Heather Turner
CEO of LB Pharmaceuticals
Explore end-to-end solutions throughout development — from portfolio optimization and regulatory strategy, to Phase I-IV clinical trials, market access planning, and more.
Our team optimizes your portfolio utilizing integrated expert clinical, regulatory, and market access strategies, enabling earlier and more informed risk-reward decisions.
Our multi-disciplinary early phase approach accelerates the path to proof of concept by integrating diverse expertise to optimize study design, generate robust clinical evidence, and reduce gaps between development phases.
We deliver whole-study solutions with integrated strategies that ensure safety, data integrity, and regulatory compliance. We design patient-informed protocols that remove participation barriers, accelerate enrollment, and increase the likelihood of successful drug launches.
Our team of former regulators and HTA professionals provide tailored regulatory, compliance, and market access strategies across specialized therapeutic areas, creating customized pathways to maximize global market reach throughout your product's lifecycle.
We enhance your product's value story through post-approval studies and holistic lifecycle management services that satisfy regulators and payers while building stakeholder trust and maximizing your drug's market impact throughout its entire lifecycle.
ParexelAI leverages our full suite of AI capabilities to deliver with greater speed, quality, and efficiency.
![]()
FSP Integrated Solutions
Our FSP solutions combine talent, expertise, technology, and global scale to help sponsors increase productivity, respond to changing pipeline demands, and bring therapies to patients faster.
Utilize our expertise across therapeutic areas, combining innovative trial designs, leading clinical and regulatory expertise, global reach, and a passion for changing patient lives.
Our team delivers high-quality clinical trials through forward-thinking medical expertise across multiple indications by combining strategic insight with operational excellence to support programs of all sizes.
Our infectious disease and vaccines cro services help treat and prevent life-threatening illnesses. Learn how our team of experts can aid in any complex trial.
Discover our inflammation and immunology CRO services. We bring agile support and a unique MOA-driven model to inflammation and immunology.
Parexel is a leading Oncology CRO with more than 80 ex-agency regulators and nearly 2,500 sites globally. Learn more about our oncology indications.
As a leading neuroscience CRO, we leverage global site relationships, specialized resources, and indication-specific expertise to accelerate breakthroughs in neurological and psychiatric treatments for patients worldwide.
As a top hematology CRO, our integrated teams use advanced analytics and real-world evidence to optimize hematology trial outcomes, ensuring faster, more effective drug development.
Rethinking strategies for rescue treatment in wet AMD and retinal vascular disease clinical trials
Learn more
Our experts help you stay at the forefront of the industry — and ahead of change.

Clinical Trialblazers
Step into the world of biotech leaders and hear the untold stories behind their journeys to bring breakthrough innovations to life.
Honest conversations with the experts shaping what's next
Thinking about joining a clinical trial? Learn the drug development process, what it’s like to participate, how to find a trial, and answers to frequently asked questions.
Clinical trials provide patients with access to innovative investigational treatments that advance medical research. Participation requires careful consideration that weighs both the benefits and risks.

Patient Stories
Clinical study participation represents a deeply personal decision with potentially far-reaching impact, as evidenced by these inspiring individual stories that highlight both the life-changing potential for participants and the broader advancement of healthcare for all.
We are one of the largest CROs in the world, speeding life-changing medicine to market by engaging patients With Heart™. Learn about who we are, what we do, and what we believe.
With decades of biopharmaceutical leadership experience and a deep dedication to patients, our executive team drives us forward in delivering better trials, faster.
Find key information on our policies, strategies, pay data, and more.
Explore end-to-end solutions throughout development — from portfolio optimization and regulatory strategy, to Phase I-IV clinical trials, market access planning, and more.
Our team optimizes your portfolio utilizing integrated expert clinical, regulatory, and market access strategies, enabling earlier and more informed risk-reward decisions.
Our multi-disciplinary early phase approach accelerates the path to proof of concept by integrating diverse expertise to optimize study design, generate robust clinical evidence, and reduce gaps between development phases.
We deliver whole-study solutions with integrated strategies that ensure safety, data integrity, and regulatory compliance. We design patient-informed protocols that remove participation barriers, accelerate enrollment, and increase the likelihood of successful drug launches.
Our team of former regulators and HTA professionals provide tailored regulatory, compliance, and market access strategies across specialized therapeutic areas, creating customized pathways to maximize global market reach throughout your product's lifecycle.
We enhance your product's value story through post-approval studies and holistic lifecycle management services that satisfy regulators and payers while building stakeholder trust and maximizing your drug's market impact throughout its entire lifecycle.
ParexelAI leverages our full suite of AI capabilities to deliver with greater speed, quality, and efficiency.
![]()
FSP Integrated Solutions
Our FSP solutions combine talent, expertise, technology, and global scale to help sponsors increase productivity, respond to changing pipeline demands, and bring therapies to patients faster.
Utilize our expertise across therapeutic areas, combining innovative trial designs, leading clinical and regulatory expertise, global reach, and a passion for changing patient lives.
Our team delivers high-quality clinical trials through forward-thinking medical expertise across multiple indications by combining strategic insight with operational excellence to support programs of all sizes.
Our infectious disease and vaccines cro services help treat and prevent life-threatening illnesses. Learn how our team of experts can aid in any complex trial.
Discover our inflammation and immunology CRO services. We bring agile support and a unique MOA-driven model to inflammation and immunology.
Parexel is a leading Oncology CRO with more than 80 ex-agency regulators and nearly 2,500 sites globally. Learn more about our oncology indications.
As a leading neuroscience CRO, we leverage global site relationships, specialized resources, and indication-specific expertise to accelerate breakthroughs in neurological and psychiatric treatments for patients worldwide.
As a top hematology CRO, our integrated teams use advanced analytics and real-world evidence to optimize hematology trial outcomes, ensuring faster, more effective drug development.
Rethinking strategies for rescue treatment in wet AMD and retinal vascular disease clinical trials
Learn more
Our experts help you stay at the forefront of the industry — and ahead of change.

Clinical Trialblazers
Step into the world of biotech leaders and hear the untold stories behind their journeys to bring breakthrough innovations to life.
Honest conversations with the experts shaping what's next
Thinking about joining a clinical trial? Learn the drug development process, what it’s like to participate, how to find a trial, and answers to frequently asked questions.
Clinical trials provide patients with access to innovative investigational treatments that advance medical research. Participation requires careful consideration that weighs both the benefits and risks.

Patient Stories
Clinical study participation represents a deeply personal decision with potentially far-reaching impact, as evidenced by these inspiring individual stories that highlight both the life-changing potential for participants and the broader advancement of healthcare for all.
We are one of the largest CROs in the world, speeding life-changing medicine to market by engaging patients With Heart™. Learn about who we are, what we do, and what we believe.
With decades of biopharmaceutical leadership experience and a deep dedication to patients, our executive team drives us forward in delivering better trials, faster.
Find key information on our policies, strategies, pay data, and more.
BIO
CEO of LB Pharmaceuticals
Heather Turner has served as the Chief Executive Officer and director of LB Pharmaceuticals since November 2024. Previously, Ms. Turner was President and CEO of Carmot Therapeutics from January 2023 to June 2024. From September 2022 to December 2022 she was COO. As CEO she completed a $150 million cross over round of financing as well as successfully orchestrated a dual track IPO/strategic transaction process which ultimately resulted in the acquisition of Carmot by Roche for $3.1 billion. In addition to the transactions, Ms. Turner also built a very successful team growing Carmot from approximately 35 people to approximately 70 people which included leadership in key functions such as CMC, Quality, Finance, Legal and HR. Before Carmot, Ms. Turner served as Chief General Counsel and Secretary at Lyell Immunopharma, Inc. Notably, she oversaw the execution of the company’s $400 million Series C financing and the fourth largest Nasdaq IPO which raised gross proceeds of approximately $425 million. In addition, Ms. Turner oversaw numerous strategic partnerships including the Company’s development and commercialization partnership with GSK which included a $200 million investment. Prior to Lyell, Ms. Turner served as Executive Vice President, General Counsel and Secretary of Sangamo Therapeutics, Inc. a publicly traded gene therapy and gene editing company. Ms. Turner served as Executive Vice President, General Counsel and Head of Portfolio Strategy at Atara Biotherapeutics, Inc., a publicly-traded allogeneic cell therapy company. At Atara, in addition to legal and portfolio strategy, Ms. Turner oversaw human resources as well as medical affairs. Prior to Atara, Ms. Turner served as General Counsel and Secretary at Orexigen Therapeutics, Inc. a publicly-traded company focused on metabolic diseases. During her tenure at Orexigen, Ms. Turner oversaw the legal, human resources, government affairs and facilities functions. Ms. Turner started her career at Cooley as a corporate securities associate. Ms. Turner received her J.D. from UCLA School of Law and her B.A. in Environmental Studies from the University of California, Santa Barbara.